Financhill is a comprehensive financial analysis platform that provides stock analysis, market data, investment tools, and educational resources to help investors make informed decisions.

How do I get started with Financhill?

You can start by creating a free account, exploring our stock analysis tools, setting up a watchlist, or trying our 7-day trial for full access to all premium features.

What features does Financhill offer?

Financhill offers stock analysis, technical charts, fundamental data, earnings information, dividend tracking, portfolio management, market screening tools, and educational resources.

What are 10K annual reports?

10K reports are comprehensive annual reports filed by public companies with the SEC, containing detailed financial statements, business operations, risk factors, and management discussion.

How often are annual reports updated?

Annual reports are typically filed once per year, usually within 60-90 days after the company's fiscal year end. We update our database as soon as new reports become available.

How do I analyze HALO stock?

Use our comprehensive analysis tools including technical charts, fundamental metrics, earnings data, and Stock Score to evaluate HALO investment potential.

What is HALO stock price today?

Get real-time HALO stock price, historical data, and price charts on Financhill. Track HALO performance with our advanced analysis tools.

Is HALO a good investment?

Evaluate HALO investment potential using our Stock Score, fundamental analysis, technical indicators, and earnings data. Consider your risk tolerance and investment goals.

How to buy HALO stock?

To buy HALO stock, open a brokerage account, research the company using our analysis tools, and place your order through your broker. Always do your own research before investing.

What is the market cap of HALO?

View detailed market capitalization data and company valuation metrics for HALO on our comprehensive analysis page.

What is the P/E ratio of HALO?

Use our fundamental analysis tools to view HALO P/E ratio and compare valuation metrics with industry peers.

What are HALO earnings?

View HALO earnings data, quarterly results, revenue growth, and profit margins on our comprehensive earnings analysis page. Track earnings trends and analyst estimates.

Back

Halozyme Therapeutics, Inc. 10K Form

Buy

HALO
Halozyme Therapeutics, Inc.

Last Price:

$68.44

Seasonality Move:

5.49%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-05-07	10Q	HALO/Halozyme Therapeutics, Inc. Quarterly
2023-11-06	10Q	HALO/Halozyme Therapeutics, Inc. Quarterly
2023-08-08	10Q	HALO/Halozyme Therapeutics, Inc. Quarterly
2023-05-09	10Q	HALO/Halozyme Therapeutics, Inc. Quarterly
2022-11-08	10Q	HALO/Halozyme Therapeutics, Inc. Quarterly
2022-08-09	10Q	HALO/Halozyme Therapeutics, Inc. Quarterly

Receive HALO News And Ratings

See the #1 stock for the next 7 days that we like better than HALO

HALO Financial Statistics

Sales & Book Value

Annual Sales:	$1B
Cash Flow:	$175.6M
Price / Cash Flow:	14.26
Annual Sales:	$4.29
Price / Book:	15.96

Profitability

EPS (TTM):	4.75740
Net Income (TTM):	$595.5M
Gross Margin:	$784.9M
Return on Equity:	139.43%
Return on Assets:	27.69%

Halozyme Therapeutics, Inc. Earnings Forecast

Key Halozyme Therapeutics, Inc. Financial Ratios

The Gross Profit Margin over the past 24 years for HALO is 77.30%.
The Selling, General & Administrative Expenses for HALO have been equal to 15.20% of Gross Profit Margin.
The Research & Development expenses have been 7.79% of Revenue.
The Interest Expense is 4.07% of Operating Income.
The Net Earning history of HALO is 43.74% of Total Revenues.
Per Share Earnings over the last 24 years have been positive in 12 years.

Halozyme Therapeutics, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange:	NASDAQ
Industry:	Biotechnology
Sector:	Health Care
Current Symbol:	HALO
CUSIP:	40637H
Website:	halozyme.com

Debt

Debt-to-Equity Ratio:	3
Current Ratio:	1.59
Quick Ratio:	1.26

Price-to-Earnings

Trailing P/E Ratio:	19.94
Forward P/E Ratio:	8.41

HALO Technical Analysis vs Fundamental Analysis

Buy

Halozyme Therapeutics, Inc. (HALO) is a Buy

Is Halozyme Therapeutics, Inc. a Buy or a Sell?

Halozyme Therapeutics, Inc. stock is rated a Buy

The current Halozyme Therapeutics, Inc. [HALO] share price is $68.41. The Score for HALO is 68, which is 36% above its historic median score of 50, and infers lower risk than normal.